Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD. METHODS: CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3. RESULTS: 11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not. CONCLUSION: This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Key biomarkers include polyQ-Htt and Tau, which are detected in the CSF, as well as BDNF, which is measurable in the blood [253,254,255,256].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [255]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unified Huntington's disease rating scale: Reliability and consistency
(1996) · Movement Disorders · doi:10.1002/mds.870110204 · Cited by 2,079
Differential behavioral effects in frontal lobe disease
Benton, A. L. (1968) · Neuropsychologia · doi:10.1016/0028-3932(68)90038-9 · Cited by 1,431
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Unified Huntington's disease rating scale: reliability and consistency
Kremer, H. P. H. (1996) · Radboud Repository (Radboud University) · Cited by 1,059
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Langbehn, D., Brinkman, R., Falush, D., Paulsen, J., Hayden, M., & on behalf of an International Huntington's Disease Collaborative Group (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00241.x · Cited by 817
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationHuntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
CAG repeat number governs the development rate of pathology in Huntington's disease
Penney, J. B., Vonsattel, J., Macdonald, M. E., Gusella, J. F., & Myers, R. H. (1997) · Annals of Neurology · doi:10.1002/ana.410410521 · Cited by 669
Episodic and Semantic Memory: A Comparison of Amnesic and Demented Patients
Butters, N., Granholm, E., Salmon, D. P., Grant, I., & Wolfe, J. (1987) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688638708410764 · Cited by 595
Cited by
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationHuntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30124-2 · Cited by 364
Self-citationNeurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies
Yuan, A., & Nixon, R. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689938 · Cited by 290
“Furthermore, in Huntington disease (HD), CSF NfL fragment levels correlate more strongly with disease progression than do CSF tau levels (Niemela et al., 2017).”
BackgroundByrne, L. M., Rodrigues, F. B., Johnson, E. B., Wijeratne, P. A., De Vita, E., Alexander, D. C., Palermo, G., Czech, C., Schobel, S., Scahill, R. I., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7108 · Cited by 194
Alirezaei, Z., Pourhanifeh, M. H., Borran, S., Nejati, M., Mirzaei, H., & Hamblin, M. R. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01698-3 · Cited by 142
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases
Benatar, M. G., Wuu, J., McHutchison, C. A., Postuma, R. B., Boeve, B. F., Petersen, R. C., Ross, C. A., Rosen, H. J., Arias, J. J., Fradette, S., et al. (2021) · Brain · doi:10.1093/brain/awab404 · Cited by 133
Papapetropoulos, S., Pontius, A., Finger, E. C., Karrenbauer, V. D., Lynch, D. S., Brennan, M. J., Zappia, S., Koehler, W., Schöls, L. J., Hayer, S. N., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.788168 · Cited by 105
Park, Y., Nirajan, K. C., Paneque, A., & Cole, P. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126295 · Cited by 86
“Furthermore, in Huntington’s disease (HD), CSF NfL fragment levels exhibit a stronger correlation with disease progression than CSF Tau levels [96].”
BackgroundNeurofilaments: The C-Reactive Protein of Neurology
Lambertsen, K. L., Soares, C. B., Gaist, D., & Nielsen, H. H. (2020) · Brain Sciences · doi:10.3390/brainsci10010056 · Cited by 72
“• 11 premanifest and 12 manifest HD patients CSF NF-L ELISA CSF NF-L correlated with 5 year probability of disease onset, functional capacity, and total motor score [32]”
MethodSampedro, F., Pérez‐González, R., Martínez‐Horta, S., Marín‐Lahoz, J., Pagonabarraga, J., & Kulisevsky, J. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.009 · Cited by 68
Fluid and imaging biomarkers for Huntington's disease
Zeun, P., Scahill, R. I., Tabrizi, S. J., & Wild, E. J. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.004 · Cited by 61
Palermo, G., Mazzucchi, S., Vecchia, A. D., Siciliano, G., Bonuccelli, U., Azuar, C., Ceravolo, R., Lista, S., Hampel, H. J., & Baldacci, F. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02035-9 · Cited by 57
A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward
Silajdžić, E., & Björkqvist, M. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170273 · Cited by 57
“HPA axis hyperactivity has been reported in early disease stage, primar- Table 7 Mutant huntingtin in HD compared to control Analyte Result Correlates with . . . Reference mtHTT, CSF ↑ Burden [114, 119] [114, 119] Onset [114, 119] TMS [114, 119] Cognition [114, 119] Abbreviations: Mutant huntingtin (mtHTT). ily in the…”
BackgroundResultInfluentialA Glimpse of Molecular Biomarkers in Huntington’s Disease
Martínez, S. M., & Valor, L. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105411 · Cited by 51
“Neurofilaments are classified according to their molecular weight as heavy (NF-H), interme- diate (NF-M) and the most soluble light chain (NF-L).”
BackgroundInfluentialBiomarkers in neurodegenerative diseases: a broad overview
Sathish, S., & Ayyavoo, V. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00075 · Cited by 44
Parkin, G. M., Corey‐Bloom, J., Snell, C. M., Castleton, J., & Thomas, E. A. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.04.017 · Cited by 36
“These results can be compared to those previously reported by Niemelä and colleagues in the CSF of a PM + HD cohort: associations were reported between CSF NfL levels and TFC, TMS, SDMT and all Stroop subscores before correcting for age, whereas only Stroop subscores and TMS remained significant following age correcti…”
ResultNiemelä, V., Burman, J., Blennow, K., Zetterberg, H., Larsson, A. O., & Sundblom, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193492 · Cited by 36
Self-citationParbo, P., Madsen, L. S., Ismail, R., Zetterberg, H., Blennow, K., Eskildsen, S. F., Vorup-Jensen, T., & Brooks, D. J. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0574-0 · Cited by 33
Self-citationProenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease
Niemelä, V., Landtblom, A., Nyholm, D., Kneider, M., Constantinescu, R., Paucar, M., Svenningsson, P., Abujrais, S., Burman, J., Shevchenko, G., et al. (2020) · Movement Disorders · doi:10.1002/mds.28391 · Cited by 31
Self-citationThe blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
Barro, C., & Zetterberg, H. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109281 · Cited by 32
Biofluid Biomarkers in Huntington’s Disease
Rodrigues, F. B., Byrne, L. M., & Wild, E. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7825-0_17 · Cited by 30
“A head-to-head comparison of NfL and Tau in CSF suggests that NfL is more strongly associated with clinical phenotype in HD[39].”
BackgroundInfluentialPeripheral Biomarkers in Manifest and Premanifest Huntington’s Disease
Morena, E., Romano, C., Marconi, M., Diamant, S., Buscarinu, M. C., Bellucci, G., Romano, S., Scarabino, D., Salvetti, M., & Ristori, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076051 · Cited by 29
“Direct comparison of CSF levels showed better correlation between clinical tests and NfLs than with tau protein [52].”
MethodTargeting Tau to Treat Clinical Features of Huntington's Disease
Masnata, M., Salem, S., Jacquet, A. D. R., Anwer, M., & Cicchetti, F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.580732 · Cited by 27
Valverde, A., Montero‐Calle, A., Barderas, R., Calero, M., Yáñez‐Sedeño, P., Campuzano, S., & Pingarrón, J. M. (2021) · Electrochimica Acta · doi:10.1016/j.electacta.2021.137815 · Cited by 24
Evaluation of Blood Glial Fibrillary Acidic Protein as a Potential Marker in Huntington's Disease
You, H., Wu, T., Du, G., Huang, Y. M., Zeng, Y., Lin, L., Chen, D., Wu, C., Li, X., Burgunder, J., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.779890 · Cited by 24
“In HD mutation carriers, NfL is statistically correlated with clinical severity, CSF mHTT, and brain atrophy (7, 8).”
BackgroundBarschke, P., Abu‐Rumeileh, S., Shweiki, M. R. A., Barba, L., Paoletti, F. P., Oeckl, P., Steinacker, P., Halbgebauer, S., Gaetani, L., Lewerenz, J., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11187-8 · Cited by 22
“Given the urgent need for surrogate endpoints in ongoing clinical trials for HD, PDYN- and PENK-derived peptides may be used together with neurofilament light chain protein (NfL) as biomarkers of disease severity that could be potentially influenced by future disease-modifying therapies [31, 32].”
BackgroundTau: a biomarker of Huntington’s disease
Lepinay, E., & Cicchetti, F. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02230-9 · Cited by 19
Parkin, G. M., Thomas, E. A., & Corey‐Bloom, J. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105173 · Cited by 18
Dyakin, V. V., Wısnıewskı, T., & Lajtha, Á. (2021) · Symmetry · doi:10.3390/sym13030455 · Cited by 20
Tau Protein Alterations Induced by Hypobaric Hypoxia Exposure
Pena, E., Martin-Salamanca, R. S., Alam, S. E., Flores, K., & Arriaza, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020889 · Cited by 18
Aqel, S., Ahmad, J., Saleh, I., Fathima, A., Thani, A. A. A., Mohamed, W. M. Y., & Shaito, A. A. (2025) · Biology · doi:10.3390/biology14020129 · Cited by 22
Huntingtin Levels are Elevated in Hippocampal Post-Mortem Samples of Alzheimer’s Disease Brain
Axenhus, M., Winblad, B. G., Tjernberg, L. O., & Schedin‐Weiss, S. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201203125622 · Cited by 16
Role of Phosphorylated Tau and Glucose Synthase Kinase 3 Beta in Huntington’s Disease Progression
Sawant, N. A., & Reddy, P. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190851 · Cited by 14
“tau could be a good biomarker in HD [78].”
BackgroundVoysey, Z. J., Owen, N. E., Holbrook, J. A., Malpetti, M., Draoulec, C. L., Spindler, L. R. B., Goodman, A. O. G., Lázár, A. S., & Barker, R. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12700-x · Cited by 13
“In support of this, multiple studies have found strong negative correlations between NfL levels and predicted years to onset of manifest HD; in some cases, exponential [18, 19, 21, 22].”
Caron, N. S., Byrne, L. M., Lemarié, F. L., Bone, J. N., Aly, A. E.-E., Ko, S., Anderson, C., Casal, L. L., Hill, A. M., Hawellek, D. J., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00443-8 · Cited by 10
Hwang, Y. S., Oh, E., Kim, M., Lee, C. Y., Kim, H. S., Chung, S. J., Sung, Y. H., Yoon, W. T., Cho, J. H., Lee, J., et al. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120744 · Cited by 10
Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias
Llorens, F., Villar‐Piqué, A., Candelise, N., Ferrer, I., & Zerr, I. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73528 · Cited by 13
“However, a diagnostic role for t-tau in HD is excluded as no differences between HD patients compared with pre-manifest gene expansion carriers have been reported [68].”
ResultCooley, S., Petersen, K. J., Tice, C. M., Langford, D., Burdo, T. H., Roman, J., & Ances, B. M. (2024) · AIDS · doi:10.1097/qad.0000000000003861 · Cited by 11
Constantinescu, R., Blennow, K., Rosengren, L., Eriksson, B., Gudmundsdottir, T., Jansson, Y., Johnels, B., Renck, A., & Bergquist, F. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.09.024 · Cited by 7
Self-citationSkin Tau Quantification as a Novel Biomarker in Huntington's Disease
Ruíz‐Barrio, I., Vázquez‐Oliver, A., Puig‐Davi, A., Rivas‐Asensio, E., Pérez‐Pérez, J., Fernandez‐Vizuete, C., Horta‐Barba, A., Olmedo‐Saura, G., Salvat‐Rovira, N., Sampedro, F., et al. (2024) · Movement Disorders · doi:10.1002/mds.29989 · Cited by 6
Sogorb-González, M., Vendrell‐Tornero, C., Snapper, J., Stam, A., Keskin, S., Miniarikova, J., Spronck, E. A., de Haan, M., Nieuwland, R., Konstantinova, P. S., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab054 · Cited by 7
Systematic Review with Meta‐Analysis of Biofluid Markers for Huntington's Disease
Paulsen, J. S., Bovin, N. A., Clemsen, J. D., Weiss, A., Key, A. M., Janz, M. L., Pinto, A. A., Burks, D. K., Zetterberg, H., & Shannon, K. M. (2025) · Movement Disorders · doi:10.1002/mds.70067 · Cited by 5
Alpaugh, M., Lantero‐Rodriguez, J., Benedet, A. L., Manseau, U., Boutin, M., Maiuri, M., Denis, H. L., Masnata, M., Fazal, S. V., Chouinard, S., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12966-9 · Cited by 7
Self-citationKorpela, S., Sundblom, J., Zetterberg, H., Constantinescu, R., Svenningsson, P., Paucar, M., & Niemelä, V. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.122979 · Cited by 6
“Some promising cerebrospinal fluid biomarkers have recently been studied (4), of which neurofilament light protein (NfL), an axonal damage marker seems to be the most promising with association to both disease onset and clinical severity in HD (5 – 8), as well as CSF mHTT (6).”
BackgroundSelf-citationSihag, S., Naze, S., Taghdiri, F., Gumus, M., Tator, C. H., Green, R., Colella, B., Blennow, K., Zetterberg, H., Dominguez, L. G., et al. (2022) · Communications Medicine · doi:10.1038/s43856-021-00065-5 · Cited by 6
Self-citationSzejko, N., Picón, C., García‐Caldentey, J., de Yébenes, J. G., Alvarez-Cermeño, J. C., Villar, L. M., & López-Sendón, J. L. (2018) · PLoS Currents · doi:10.1371/currents.hd.280c8f9f7d9fa4f7f0c883d9f8e807da · Cited by 4
Neurofilaments in neurologic disease
Mousele, C., Holden, D., & Gnanapavan, S. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.06.010 · Cited by 7
Danna, R., Kondle, S., Amar, O., Mabourakh, M., Chen, G., Fadol, W. B., & Mohieldin, A. M. (2025) · Biology · doi:10.3390/biology14121787 · Cited by 2
Biomarkers in Huntington’s Disease
Killoran, A. (2021) · Neuromethods · doi:10.1007/978-1-0716-1712-0_10 · Cited by 3
A 14‐Year Study of Serum Glial Fibrillary Acidic Protein and Total Tau in Premanifest Huntington's
Owen, N. E., Voysey, Z. J., Holbrook, J. A., Malpetti, M., Draoulec, C. L., Spindler, L. R. B., Goodman, A. O. G., Lázár, A. S., & Barker, R. A. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70057 · Cited by 1
“This is consistent with the aforementioned studies [6] and cross-sectional studies reporting associations between plasma GFAP and more severe motor scores among other clinical measures of disease severity [5, 16], whereas plasma t-tau exhibits weaker, or no, associations [22, 23].”
Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620
Martínez‐Horta, S., Pérez‐Pérez, J., Puig‐Davi, A., Camacho, V., Pérez‐Carasol, L., Franch-Martí, C., Olmedo‐Saura, G., Fernández‐León, Á., Flotats, A., Kolinger, G. D., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-08003-0 · Cited by 1
Pérez‐Pérez, J., Olmedo‐Saura, G., Puig‐Davi, A., Pérez‐González, R., Pegueroles, J., Horta‐Barba, A., Oliver, A. V., Rivas, E. I., Alcolea, D. A., Fortea, J., et al. (2026) · Movement Disorders · doi:10.1002/mds.70550 · Cited by 1
Preventive drugs for Huntington’s disease: A choice-based conjoint survey of patient preferences
Parrish, M. C., Hanson‐Kahn, A., Srinivasan, V., & Grimes, K. (2022) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.372 · Cited by 1
Cerebrospinal Fluid Biomarkers in Huntington’s Disease
Pio, F., & Leavitt, B. R. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-32815-2_2 · Cited by 1
Cerebrospinal Fluid Markers of Medium Spiny Neuron Injury in Huntington's Disease
Bang, J., & Ross, C. A. (2021) · Movement Disorders · doi:10.1002/mds.28386 · Cited by 1
“In HD, CSF NfL correlates with disease stage, motor and cognitive impairment, functional impairment, and brain volume loss.(9,10) CSF NfL was recently shown to be elevated in a premanifest cohort decades before predicted clinical onset.”
BackgroundThe role of neurofilament light chain in the context of neurological disorders
Taluntienė, V., Motiekaitytė, R., Kizlaitienė, R., Giedraitienė, N., & Kaubrys, G. (2020) · Neurologijos seminarai · doi:10.29014/ns.2020.37 · Cited by 1
Murphy, M., Farag, M., & Tabrizi, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00172-x
Fluid and Imaging Markers of Huntington’s Disease
Farag, M., Scahill, R. I., Wild, E. J., & Tabrizi, S. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_11
Romero, G. I. T., Echavarría, A. M. J., Orrego-Agudelo, L. R., Turizo, L. F. P., Ibañez, M. V. C., & Álzate, J. P. (2025) · touchREVIEWS in Neurology · doi:10.17925/usn.2025.21.1.11
Grétarsdóttir, H. M., Cunningham, J. L., Rasmusson, A. J., Burman, J., Kultima, K., Paucar, M., Svenningsson, P., Constantinescu, R., & Niemelä, V. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14112-5
“This study was based on CSF samples collected within the Uppsala Huntington’s disease CSF (Uppsala HDCSF) study, an ongoing longitudinal study of individuals with Huntington’s disease and neurologically unaffected controls, (here-after referred to as “controls”), as previously described [9].”
Self-citationLiu, H., Ding, Z., Wang, Y., Moniz, H., Li, Y., Ouyang, Y., Liu, C., Andersen, J., Hua, J., Xu, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.20.753038
Metadata
- Authors
- Niemelä, V., Landtblom, A.-M., Blennow, K., & Sundblom, J.
- Affiliations
- Uppsala University (SE)
- University of Gothenburg (SE)
- Corresponding author
- Niemelä, Valter
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-02-27
- Volume
- 12
- Issue
- 2
- Pages
- e0172762
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5328385
- OpenAlex
- W2592956615
- Cited by
- 63
- References
- 31
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 11 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 9 · 2019: 4 · 2018: 7 · 2017: 1
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Åland Cultural Foundation
- The Selander Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Huntington's disease, neurofilament light chain, total tau, cerebrospinal fluid biomarkers, premanifest Huntington's disease, disease stage, disease progression, Unified Huntington's Disease Rating Scale, disease-modifying therapy
- MeSH terms
- Adult, Aged, Axons, Enzyme-Linked Immunosorbent Assay, Female, Humans, Huntington Disease, Male, Middle Aged, Mutation, Cohort Studies, Biomarkers, tau Proteins, Neurofilament Proteins, Disease Progression, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.